Drug intelligence / Profile preview

HY6-F9DHS

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (inferred From Standard mAb Practice And Animal Studies)

Overview

HY6-F9DHS is an engineered monoclonal antibody targeting fentanyl and fentanyl analogues, designed for the treatment of opioid-related overdoses and opioid use disorder. This antibody was developed by introducing specific mutations in the Fc region of an IgG1 anti-fentanyl monoclonal antibody to enhance its binding affinity to the neonatal Fc receptor (FcRn), thereby increasing its serum half-life and therapeutic efficacy. In animal models, HY6-F9DHS demonstrated extended persistence in serum compared to the wild-type antibody and provided effective protection against fentanyl-induced toxic effects[1].

Other names: HY6-F9DHSHY-6-F9DHSHY 6-F9DHS

Beyond the preview

Go deeper on HY6-F9DHS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY6-F9DHS.

Explore the full profile